The drug is intended to help control high blood sugar when paired with diet and exercise.
The tablets are a generic equivalent of Raleigh, N.C.-based Santarus’ Glumetza tablets, which post annual sales of about $1.2 billion in the United States.
Mumbai, India-based Sun Pharmaceuticals expects to launch the tablets within the next few weeks.
More articles on the drug market:
FDA grants priority review status to muscular dystrophy drug
FDA seeks to increase access to Naloxone
Online market for illegal drugs skyrockets: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
